Drugs / IDP-126
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial · 1 met primary | ||||||
| Phase 2 | NCT03170388 | Oct 2017 → Apr 2019 | acne | Bausch Health Americas, Inc. | Completed | Met primary |
| Phase 32 trials | ||||||
| Phase 3 | NCT04214652 | Jan 2020 → Mar 2021 | acne | Bausch Health Americas, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT04214639 | Jan 2020 → Jan 2021 | acne | Bausch Health Americas, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IDP-126 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03170388 ↗ |
| Modality | Other / unclassified | “fixed-dose, triple-combination topical acne product” PMID 38724841 ↗ May 2024 |
| Route | Topical | “fixed-dose topical clindamycin phosphate 1.2%/benzoyl peroxide (BPO) 3.1%/adapalene 0.15% (IDP-126) gel” PMID 34674160 ↗ Oct 2021 |